tradingkey.logo

Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA

ReutersJan 30, 2026 11:42 AM


Overview

  • Biotechnology firm's Q4 revenue rose 3%, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company announced FDA approvals for EYLEA HD and Libtayo


Outlook

  • Regeneron expects 2026 GAAP R&D expenses between $6.45 bln and $6.68 bln

  • Company anticipates FDA decision on EYLEA HD pre-filled syringe in Q2 2026

  • Regeneron projects 2026 GAAP gross margin on net product sales at 79%-80%


Result Drivers

  • DUPIXENT SALES - Dupixent global net sales increased 34% in Q4 2025, helped by new approvals in Japan and Europe

  • EYLEA HD DEMAND - EYLEA HD U.S. net sales rose 66% in Q4 2025 due to increased demand, despite competitive pressures

  • SANOFI COLLABORATION - Collaboration revenue from Sanofi increased due to higher share of profits from commercialization of antibodies


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$3.88 bln

$3.80 bln (19 Analysts)

Q4 Adjusted EPS

Beat

$11.44

$10.62 (19 Analysts)

Q4 EPS

$7.86

Press Release: ID:nGNXbFdfdZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI